@article{I. Marie_S. Robaday_J.M. Kerleau_F. Jardin_H. Levesque_2007, place={Pavia, Italy}, title={Typhlitis as a complication of alemtuzumab therapy}, volume={92}, url={https://haematologica.org/article/view/4457}, DOI={10.3324/haematol.11440}, abstractNote={Alemtuzumab is a humanized monoclonal antibody directed against lymphocytes through the CD-52 receptor, an antigen being found on > 95% of peripheral blood lymphocytes and monocytes, and to a smaller extent on granulocytes.<a class="xref-bibr" href="#ref-1" id="xref-ref-1-1">1</a>–<a class="xref-bibr" href="#ref-7" id="xref-ref-7-1">7</a> It is an effective immunotherapeutic agent in patients with malignancies such as non-Hodgkin lymphoma, B cell chronic lymphocytic leukemia and T cell prolymphocytic leukemia.<a class="xref-bibr" href="#ref-1" id="xref-ref-1-2">1</a>–<a class="xref-bibr" href="#ref-7" id="xref-ref-7-2">7</a> Adverse side effects are increasingly recognized in patients receiving alemtuzumab, mainly including fever, rigors, nausea/vomiting, skin rash; other severe alemtuzumab-related reactions have also been described, such as lymphopenia and neutropenia leading to both opportunistic (e.g. cytomegalovirus) and non-opportunistic infections.<a class="xref-bibr" href="#ref-7" id="xref-ref-7-3">7</a>–<a class="xref-bibr" href="#ref-10" id="xref-ref-10-1">10</a> Digestive complications have more rarely been described, i.e.: gastroenteritis and peritonitis.<a class="xref-bibr" href="#ref-10" id="xref-ref-10-2">10</a&gt; We recently observed a case of particular interest as the patient with T cell prolymphocytic leukaemia treated with alemtuzumab, exhibited symptomatic reactivation of CMV infection and developed subsequently typhlitis}, number={5}, journal={Haematologica}, author={I. Marie and S. Robaday and J.M. Kerleau and F. Jardin and H. Levesque}, year={2007}, month={May}, pages={e62-e63} }